Piribedil is a small molecule drug with a maximum clinical trial phase of IV and is indicated in parkinson disease. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents. Its therapeutic use is listed as antiparkinsonian agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Trivastal and Piribendyl. Its PubChem CID is 4850.
Piribedil
| CAS No | 3605-01-4 |
|---|---|
| Molecular Formula | C16H18N4O2 |
| Molecular Weight | 298.34 g/mol |
| Synonyms | 2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Piribedil is a small molecule drug with a maximum clinical trial phase of IV and is indicated in parkinson disease. It is grouped under the following drug class(es): Dopamine agents and Neurotransmitter agents.
The listed CAS number is 3605-01-4.
The listed molecular formula is C16H18N4O2.
The listed molecular weight is 298.34 g/mol.
2-[4-(1,3-benzodioxol-5-ylmethyl)piperazin-1-yl]pyrimidine.
The source lists Trivastal and Piribendyl.